MedTrace Logo

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

NCT07505004 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-04-01

No results posted yet for this study

Summary

A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)

Conditions

  • Focal Epilepsy

Interventions

DRUG

40 mg/day vormatrogine for 12 weeks

Once daily oral

DRUG

30 mg/day vormatrogine for 12 weeks

Once daily oral

DRUG

20 mg/day vormatrogine for 12 weeks

Once daily oral

DRUG

Placebo

Once daily oral

Sponsors & Collaborators

Principal Investigators

  • Praxis Precision Medicines · Praxis Precision Medicines

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-29
Primary Completion
2027-01-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07505004 on ClinicalTrials.gov